Answers are grounded in this paper and cite their sources.
BACKGROUND: In monarchE, 2 years of abemaciclib plus endocrine therapy (ET) significantly reduced the risk of recurrence and mortality in patients with node-positive, high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer. This analysis provides additional efficacy data based on nodal subgroups. PATIENTS AND METHODS: Three nodal subgroups were analyzed in cohort 1, a population comprising 91% of the patients in monarchE: N1 high-risk (1-3 positive nodes with grade 3 tumors and/or tumor size ≥5 cm), N2 [4-9 positive axillary lymph node (ALN)], and N3 (≥10 positive ALN). Median follow-up was 76.8 months. Efficacy outcomes for invasive disease-free survival (IDFS) and distant recurrence-free survival (DRFS) using Kaplan-Meier methods and baseline characteristics are reported for nodal subgroups. RESULTS: Kaplan-Meier analyses for IDFS and DRFS highlighted consistent and durable efficacy across nodal subgroups. Within the N1 high-risk group, 68.6% of tumors were grade 3; 57.6% of grade 3 tumors were <5 cm. In ET arm, recurrence risk in the N1 high-risk group was similar to N2. CONCLUSIONS: The similar recurrence risk for patients in the N1 high-risk and N2 subgroups, and consistent efficacy across nodal subgroups, support addition of 2 years of adjuvant abemaciclib to ET to improve outcomes in patients meeting monarchE cohort 1 N1 high-risk, N2, or N3 criteria.
No takes yet. Share an insight, caveat, or question.
Cortés et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: